A study of sleep manifestations in patients with caspr2 antibody-associated disease

Yan HUANG,Hongzhi GUAN,Qing LIU,Honglin HAO,Heyang SUN,Haitao REN,Qiang LU,Liri JIN,Lixin ZHOU,Junyi ZHANG,Bin PENG,Liying CUI
DOI: https://doi.org/10.3969/j.issn.1006-2963.2018.06.004
2018-01-01
Abstract:Objective A study was undertaken to describe the clinical spectrum , especially sleep disorder in Nine patients associated with CASPR2 antibody.Methods Nine consecutive patients were identified with CASPR2 antibody in the Department of Neurology , Peking Union Medical College Hospital between December 2014 to June 2017. The characteristics of the 9 patients were studied from several aspects such as clinical presentation ,imaging ,polysomnography (PSG) ,cerebrospinal fluid and serum test. These patients were identified with Morvan syndrome (n= 7) , peripheral nervous system hyperexcitability (n= 1) , limbic encephalitis (n=1).Insomnia present in all the patients , 4 patients had dream enactment behavior , 2 patients with excessive motor activity.5 patients completed PSG examination.PSG in 2 patients with Morvan syndrome revealed complete absence of recognizable sleep ;PSG in the other 2 patients with Morvan syndrome documented severe insomnia , lack of cyclic sleep organization with a predominance of stage 1 NREM intermixed with brief REM sleep episodes ,and a marked reduction of spindles and delta sleep ,period limb movement index (PLMI) in 1 patient was 44.9/h. The sleep efficiency of the patient with peripheral nervous system hyperexcitability was 42%.8 patients received immunotherapy (human immunoglobulin and/or corticosteroids) ,Sleep disorders and other symptoms resolved completely or almost completely in 7 patients.1 patient died from septic shock after 6 months.1 patient died from sudden cardiac death before immunotherapy.Conclusions The resulting syndrome may vary among patients with Caspr2 antibodies , including Morvan syndrome , neuromyotonia , limbic encephalitis.Severe insomnia isa cardinal manifestations of the patients associated with Caspr 2 antibodies. Recognition of this spectrum of symptoms and consideration of the protracted clinical course are important for early diagnosis of this disorder. Prompt immunotherapy often result in improvements.
What problem does this paper attempt to address?